EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Sotalol prophylaxis was efficient and safe for supraventricular tachycardia in early infancy

Caroline Evertsson iD, Håkan Eliasson, Cecilia Pegelow Halvorsen

Acta Paediatrica · 2024

DOI: 10.1111/apa.17357 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Acta Paediatrica, 2024. Verfasst von Caroline Evertsson und 2 weiteren Autor:innen. Beteiligte Einrichtung: Sachs' Children and Youth Hospital, Stockholm South General Hospital (Södersjukhuset), Stockholm, Sweden. Hauptthemen laut MEDLINE: Sotalol, Tachycardia, Supraventricular, Anti-Arrhythmia Agents. Die Arbeit nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

There is no consensus on the best prophylaxis for supraventricular tachycardia (SVT) in infancy. We studied the efficacy and safety of sotalol.

Method

This retrospective study comprised infants diagnosed with SVT before 1 year of age and treated with sotalol during 2002–2018 in Stockholm, Sweden. The patients' characteristics, comorbidities, sotalol dosages, QT intervals and outcomes were extracted from their medical records.

Results

We studied 85 infants (65% boys) with a median age of eight (range 0–288) days at the time of diagnosis, including 78 with re‐entry tachycardia. Sotalol was completely or partially successful in the 67/75 patients who completed the treatment, as well as in four of the seven patients with other tachycardia mechanisms. The 48 infants with postnatal debut had significantly higher success rates than the 27 with foetal debut (96% vs. 78%, p = 0.04). Prolongation of corrected QT (QTc) intervals of ≥450 ms occurred in 16% of the total cohort and two patients with QTc intervals of ≥500 ms had their treatment changed. There were no cases of proarrhythmia after sotalol treatment.

Conclusion

Sotalol provided effective and safe prophylaxis for SVT during infancy. QTc prolongation rarely caused treatment discontinuation and there were no cases of proarrhythmia.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SotalolTachycardia, SupraventricularAnti-Arrhythmia AgentsHumansMaleFemaleRetrospective StudiesInfantInfant, NewbornTreatment Outcome

Stichwörter der Autor:innen

Wolff‐Parkinson‐White syndromearrhythmia prophylaxissotalolsupraventricular tachycardiatreatment efficacy

Substanzen

SotalolAnti-Arrhythmia Agents

Autor:innen und Institutionen

  • Sachs' Children and Youth Hospital, Stockholm South General Hospital (Södersjukhuset), Stockholm, Sweden.
  • Paediatric Cardiology Department, Astrid Lindgren Children's Hospital, Karolinska University Hospital, Stockholm, Sweden.
  • Department of Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden.
  • Department of Clinical Science and Education, Stockholm South General Hospital (Södersjukhuset), Karolinska Institutet, Stockholm, Sweden.

ORCID-Profile: Caroline Evertsson

Zitieren

APA

Evertsson, C., Eliasson, H., & Halvorsen, C. P. (2024). Sotalol prophylaxis was efficient and safe for supraventricular tachycardia in early infancy. Acta Paediatrica. https://doi.org/10.1111/apa.17357

Vancouver

Evertsson C, Eliasson H, Halvorsen CP. Sotalol prophylaxis was efficient and safe for supraventricular tachycardia in early infancy. Acta Paediatrica. 2024. doi:10.1111/apa.17357

BibTeX
@article{Evertsson2024,
  author = {Evertsson, Caroline and Eliasson, Håkan and Halvorsen, Cecilia Pegelow},
  title = {Sotalol prophylaxis was efficient and safe for supraventricular tachycardia in early infancy},
  journal = {Acta Paediatrica},
  year = {2024},
  doi = {10.1111/apa.17357}
}
Kostenlos starten →